23 results on '"Mitchell LB"'
Search Results
2. Addendum to 'Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations: a medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology': public safety issues in patients with implantable defibrillators: a scientific statement from the American Heart Association and the Heart Rhythm Society.
- Author
-
Epstein AE, Baessler CA, Curtis AB, Estes NA 3rd, Gersh BJ, Grubb B, Mitchell LB, and American Heart Association
- Published
- 2007
3. Prophylactic therapy to prevent atrial arrhythmia after cardiac surgery.
- Author
-
Mitchell LB
- Published
- 2007
- Full Text
- View/download PDF
4. Survival after coronary revascularization among patients with kidney disease.
- Author
-
Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA, and Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease Investigators
- Published
- 2004
5. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.
- Author
-
Teo KK, Mitchell LB, Pogue J, Bosch J, Dagenais G, Yusuf S, and HOPE Investigators
- Published
- 2004
6. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
- Author
-
Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, Bochenek A, and Toft E
- Subjects
- Aged, Anisoles adverse effects, Anti-Arrhythmia Agents adverse effects, Argentina, Atrial Fibrillation etiology, Atrial Fibrillation physiopathology, Atrial Flutter etiology, Atrial Flutter physiopathology, Double-Blind Method, Electrocardiography, Europe, Female, Humans, India, Infusions, Intravenous, Male, Middle Aged, North America, Prospective Studies, Pyrrolidines adverse effects, Time Factors, Treatment Outcome, Anisoles administration & dosage, Anti-Arrhythmia Agents administration & dosage, Atrial Fibrillation drug therapy, Atrial Flutter drug therapy, Coronary Artery Bypass adverse effects, Heart Valve Prosthesis Implantation adverse effects, Pyrrolidines administration & dosage
- Abstract
Background: Postoperative atrial arrhythmias are common and are associated with considerable morbidity. This study was designed to evaluate the efficacy and safety of vernakalant for the conversion of atrial fibrillation (AF) or atrial flutter (AFL) after cardiac surgery., Methods and Results: This was a prospective, randomized, double-blind, placebo-controlled trial of vernakalant for the conversion of AF or AFL after coronary artery bypass graft, valvular surgery, or both. Patients were randomly assigned 2:1 to receive a 10-minute infusion of 3 mg/kg vernakalant or placebo. If AF or AFL was present after a 15-minute observation period, then a second 10-minute infusion of 2 mg/kg vernakalant or placebo was given. The primary end point was the conversion of postcardiac surgery AF or AFL to sinus rhythm within 90 minutes of dosing. In patients with AF, 47 of 100 (47%) who received vernakalant converted to SR compared with 7 of 50 (14%) patients who received placebo (P<0.001). The median time to conversion was 12 minutes. Vernakalant was not effective in converting postoperative AFL to sinus rhythm. Two serious adverse events occurred within 24 hours of vernakalant administration (hypotension and complete atrioventricular block). There were no cases of torsades de pointes, sustained ventricular tachycardia, or ventricular fibrillation. There were no deaths., Conclusions: Vernakalant was safe and effective in the rapid conversion of AF to sinus rhythm in patients who had AF after cardiac surgery., Clinical Trial Registration: clinicaltrials.gov. Identifier: NCT00125320.
- Published
- 2009
- Full Text
- View/download PDF
7. Validation of a new simple scale to measure symptoms in atrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale.
- Author
-
Dorian P, Guerra PG, Kerr CR, O'Donnell SS, Crystal E, Gillis AM, Mitchell LB, Roy D, Skanes AC, Rose MS, and Wyse DG
- Subjects
- Age Factors, Aged, Atrial Fibrillation therapy, Canada, Emergency Medical Services statistics & numerical data, Female, Hospitalization, Humans, Male, Middle Aged, Multivariate Analysis, Quality of Life, Reproducibility of Results, Sex Factors, Atrial Fibrillation physiopathology, Atrial Fibrillation psychology, Health Status, Severity of Illness Index, Surveys and Questionnaires standards
- Abstract
Background: Atrial fibrillation (AF) is commonly associated with impaired quality of life. There is no simple validated scale to quantify the functional illness burden of AF. The Canadian Cardiovascular Society Severity in Atrial Fibrillation (CCS-SAF) scale is a bedside scale that ranges from class 0 to 4, from no effect on functional quality of life to a severe effect on life quality. This study was performed to validate the scale., Methods and Results: In 484 patients with documented AF (62.2+/-12.5 years of age, 67% men; 62% paroxysmal and 38% persistent/permanent), the SAF class was assessed and 2 validated quality-of-life questionnaires were administered: the SF-36 generic scale and the disease-specific AFSS (University of Toronto Atrial Fibrillation Severity Scale). There is a significant linear graded correlation between the SAF class and measures of symptom severity, physical and emotional components of quality of life, general well-being, and health care consumption related to AF. Patients with SAF class 0 had age- and sex-standardized SF-36 scores of 0.15+/-0.16 and -0.04+/-0.31 (SD units), that is, units away from the mean population score for the mental and physical summary scores, respectively. For each unit increase in SAF class, there is a 0.36 and 0.40 SD unit decrease in the SF-36 score for the physical and mental components. As the SAF class increases from 0 to 4, the symptom severity score (range, 0 to 35) increases from 4.2+/-5.0 to 18.4+/-7.8 (P<0.0001)., Conclusions: The CCS-SAF scale is a simple semiquantitative scale that closely approximates patient-reported subjective measures of quality of life in AF and may be practical for clinical use.
- Published
- 2009
- Full Text
- View/download PDF
8. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
- Author
-
Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, and Wyse DG
- Subjects
- Adrenergic beta-Antagonists therapeutic use, Amiodarone therapeutic use, Anti-Arrhythmia Agents adverse effects, Anti-Arrhythmia Agents therapeutic use, Anticoagulants therapeutic use, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Atrial Fibrillation mortality, Atrial Fibrillation physiopathology, Calcium Channel Blockers therapeutic use, Combined Modality Therapy, Comorbidity, Digoxin therapeutic use, Electric Countershock, Follow-Up Studies, Heart Rate, Humans, Models, Cardiovascular, Myocardial Contraction, Phenethylamines therapeutic use, Proportional Hazards Models, Retrospective Studies, Risk, Stroke etiology, Stroke prevention & control, Sulfonamides therapeutic use, Survival Analysis, Treatment Failure, Treatment Outcome, Warfarin therapeutic use, Atrial Fibrillation therapy
- Abstract
Background: The AFFIRM Study showed that treatment of patients with atrial fibrillation and a high risk for stroke or death with a rhythm-control strategy offered no survival advantage over a rate-control strategy in an intention-to-treat analysis. This article reports an "on-treatment" analysis of the relationship of survival to cardiac rhythm and treatment as they changed over time., Methods and Results: Modeling techniques were used to determine the relationships among survival, baseline clinical variables, and time-dependent variables. The following baseline variables were significantly associated with an increased risk of death: increasing age, coronary artery disease, congestive heart failure, diabetes, stroke or transient ischemic attack, smoking, left ventricular dysfunction, and mitral regurgitation. Among the time-dependent variables, the presence of sinus rhythm (SR) was associated with a lower risk of death, as was warfarin use. Antiarrhythmic drugs (AADs) were associated with increased mortality only after adjustment for the presence of SR. Consistent with the original intention-to-treat analysis, AADs were no longer associated with mortality when SR was removed from the model., Conclusions: Warfarin use improves survival. SR is either an important determinant of survival or a marker for other factors associated with survival that were not recorded, determined, or included in the survival model. Currently available AADs are not associated with improved survival, which suggests that any beneficial antiarrhythmic effects of AADs are offset by their adverse effects. If an effective method for maintaining SR with fewer adverse effects were available, it might be beneficial.
- Published
- 2004
- Full Text
- View/download PDF
9. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.
- Author
-
Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, Mitchell LB, Green MS, Klein GJ, and O'Brien B
- Subjects
- Aged, Amiodarone adverse effects, Anti-Arrhythmia Agents adverse effects, Female, Humans, Male, Middle Aged, Proportional Hazards Models, Risk Factors, Tachycardia, Ventricular drug therapy, Tachycardia, Ventricular mortality, Ventricular Fibrillation drug therapy, Ventricular Fibrillation mortality, Amiodarone therapeutic use, Anti-Arrhythmia Agents therapeutic use, Defibrillators, Implantable adverse effects, Tachycardia, Ventricular therapy, Ventricular Fibrillation therapy
- Abstract
Background: Patients surviving ventricular fibrillation (VF) or sustained ventricular tachycardia (VT) are at a high risk of death due to a recurrence of arrhythmia. The implantable cardioverter defibrillator (ICD) terminates VT or VF, but it is not known whether this device prolongs life in these patients compared with medical therapy with amiodarone., Methods and Results: A total of 659 patients with resuscitated VF or VT or with unmonitored syncope were randomly assigned to treatment with the ICD or with amiodarone. The primary outcome measure was all-cause mortality, and the secondary outcome was arrhythmic death. A total of 328 patients were randomized to receive an ICD. A thoracotomy was done in 33, no ICD was implanted in 18, and the rest had a nonthoracotomy ICD. All 331 patients randomized to amiodarone received it initially. At 5 years, 85.4% of patients assigned to amiodarone were still receiving it at a mean dose of 255 mg/day, 28.1% of ICD patients were also receiving amiodarone, and 21.4% of amiodarone patients had received an ICD. A nonsignificant reduction in the risk of death was observed with the ICD, from 10.2% per year to 8.3% per year (19.7% relative risk reduction; 95% confidence interval, -7.7% to 40%; P=0.142). A nonsignificant reduction in the risk of arrhythmic death was observed, from 4.5% per year to 3.0% per year (32.8% relative risk reduction; 95% confidence interval, -7.2% to 57.8%; P=0.094)., Conclusions: A 20% relative risk reduction occurred in all-cause mortality and a 33% reduction occurred in arrhythmic mortality with ICD therapy compared with amiodarone; this reduction did not reach statistical significance.
- Published
- 2000
- Full Text
- View/download PDF
10. Spatial features in body-surface potential maps can identify patients with a history of sustained ventricular tachycardia.
- Author
-
Hubley-Kozey CL, Mitchell LB, Gardner MJ, Warren JW, Penney CJ, Smith ER, and Horácek BM
- Subjects
- Case-Control Studies, Discriminant Analysis, Electrophysiology, Female, Humans, Male, Middle Aged, Myocardial Infarction physiopathology, Predictive Value of Tests, Risk Factors, Sensitivity and Specificity, Tachycardia, Ventricular epidemiology, Tachycardia, Ventricular physiopathology, Body Surface Potential Mapping, Tachycardia, Ventricular diagnosis
- Abstract
Background: Regional disparities of ventricular primary-repolarization properties contribute to an electrophysiological substrate for arrhythmias. Such disparities can be assessed from body-surface distributions of ECG QRST areas. Our objective was to isolate and test those features of QRST-area distributions that would be suitable for identifying patients at risk for life-threatening ventricular arrhythmias., Methods and Results: We recorded ECGs simultaneously from 120 leads during sinus rhythm for 204 patients taking no antiarrhythmic drugs: half had had sustained ventricular tachycardia (VT); the other half, a myocardial infarction but no history of VT. For each patient, we calculated the QRST area in each lead and, using Karhunen-Loeve (K-L) expansion, reduced these data to 16 coefficients (each relating to one spatial feature, an eigenvector, derived from the total set of 204 QRST-area maps). Using stepwise discriminant analysis, we selected feature subsets that best discriminated between the two groups, and we estimated by a bootstrap procedure using 1000 trials how these subsets would perform on a prospective patient population. The mean diagnostic performance of the classifier for 1000 randomly selected training sets (n = 102 in each, with both groups equally represented) increased monotonically with the number of features used for classification. The initial trend for the corresponding test sets (n = 102 in each) was the same but reversed when the number of features exceeded eight. For an optimal set of eight spatial features, the sensitivity and specificity of the classifier for detecting patients with VT in 1000 test sets were (mean +/- SD) 90.3 +/- 4.3% and 78.0 +/- 6.1%, and its positive and negative predictive accuracies were 80.7 +/- 4.2% and 89.2 +/- 4.2%, respectively. Use of QRS duration as a supplementary feature to eight K-L coefficients can, in the test sets, increase specificity to 80.9 +/- 5.4% and positive predictive accuracy to 82.8 +/- 3.9% compared with the results for the optimal number of eight K-L features alone., Conclusions: Multiple body-surface ECGs contain valuable spatial features that can identify the presence of an arrhythmogenic substrate in the myocardium of patients at risk for ventricular arrhythmias. Our results compare very favorably with those achieved by any other known test, invasive or noninvasive, for arrhythmogenicity.
- Published
- 1995
- Full Text
- View/download PDF
11. Long-term reproducibility of ventricular tachycardia induction in patients with implantable cardioverter/defibrillators. Serial noninvasive studies.
- Author
-
Gillis AM, Sheldon RS, Wyse DG, Leitch JW, Yee R, Klein GJ, Duff HJ, and Mitchell LB
- Subjects
- Aged, Electrophysiology, Female, Humans, Male, Middle Aged, Reproducibility of Results, Time Factors, Defibrillators, Implantable, Heart Function Tests, Tachycardia, Ventricular physiopathology, Tachycardia, Ventricular surgery
- Abstract
Background: Noninvasive electrophysiological studies (EPSs) can be performed in current implantable antitachycardia pacemaker/cardioverter/defibrillators (ICDs). Thus, these devices may be used as tools to study changes in the electrophysiological substrate and ventricular tachycardia characteristics over time., Methods and Results: Fifty-five patients receiving an ICD for treatment of sustained ventricular tachyarrhythmias underwent serial EPSs after implantation of the ICD. Studies were performed before hospital discharge and 1, 3, 5, 9, 12, 18, 24, and 36 months after ICD implantation. Sustained monomorphic ventricular tachycardia (VT) was induced in 37 patients (group 1) at the predischarge EPS, whereas no sustained arrhythmia could be induced in 18 patients (group 2) at baseline. Group 1 patients underwent 165 noninvasive EPSs after discharge. Sustained monomorphic VT was induced during 72% of the follow-up EPSs, ventricular fibrillation (VF) was induced during 11% of follow-up EPSs, and no sustained VT or VF was induced during 17% of follow-up visits. Sustained VT was induced at every follow-up EPS in 23 patients (62%), whereas no sustained VT/VF could be induced at least once during follow-up in 14 patients (38%). Clinical or electrophysiological variables did not predict noninducibility during follow-up. However, the probability that a patient would experience spontaneous VT decreased significantly over time in patients in whom VT was not inducible during at least 1 follow-up EPS (P = .05). Group 2 patients underwent 86 noninvasive EPSs after discharge. Sustained monomorphic VT was induced during 22% of follow-up EPSs, VF was induced during 19% of follow-up EPSs, and no sustained VT/VF could be induced during 68% of follow-up EPSs. No sustained VT/VF could be induced during every follow-up EPS in 9 patients (50%), whereas sustained monomorphic VT was induced at least once during follow-up in 7 patients (34%). Persistent noninducibility of VT during follow-up was associated with low probability of occurrence of spontaneous VT (11%), whereas inducibility of VT at least once during follow-up was associated with the occurrence of spontaneous VT (89%, P = .003)., Conclusions: Considerable variability of VT induction is observed over a lengthy period in patients presenting with sustained VT/VF. Persistent noninducibility of VT is associated with a reduced probability of spontaneous VT. These observations suggest that the substrates for inducible and spontaneous VT change in parallel over time.
- Published
- 1995
- Full Text
- View/download PDF
12. Interpretation of the results of the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) study: programmed ventricular stimulation advocates view.
- Author
-
Mitchell LB and Wyse DG
- Subjects
- Arrhythmias, Cardiac physiopathology, Electric Stimulation, Electrocardiography, Ambulatory, Electrophysiology, Exercise Test, Humans, Random Allocation, Tachycardia, Ventricular drug therapy, Tachycardia, Ventricular physiopathology, Ventricular Fibrillation drug therapy, Ventricular Fibrillation physiopathology, Anti-Arrhythmia Agents therapeutic use, Arrhythmias, Cardiac drug therapy, Heart Ventricles physiopathology
- Published
- 1994
- Full Text
- View/download PDF
13. Electrocardiographic correlates of spontaneous termination of ventricular tachycardia in patients with coronary artery disease.
- Author
-
Duff HJ, Mitchell LB, Gillis AM, Sheldon RS, Chudleigh L, Cassidy P, Chiamvimonvat N, and Wyse DG
- Subjects
- Cardiac Pacing, Artificial, Female, Humans, Male, Middle Aged, Tachycardia, Ventricular drug therapy, Tachycardia, Ventricular etiology, Anti-Arrhythmia Agents therapeutic use, Coronary Disease complications, Electrocardiography, Heart Conduction System physiopathology, Myocardial Infarction complications, Tachycardia, Ventricular physiopathology
- Abstract
Background: In vitro studies have reported that beat-to-beat variance in tachycardia cycle length and in conduction and repolarization properties can result in spontaneous termination of reentrant arrhythmias. The purpose of this study was to define the ECG patterns associated with spontaneous termination of ventricular tachycardia in humans late after myocardial infarction., Methods and Results: The QRS durations, QT intervals, and cycle lengths were measured on a beat-to-beat basis during episodes of sustained and spontaneously terminating ventricular tachycardias (VT) induced at antiarrhythmic drug-free and drug-assessment electrophysiological studies. Twenty-six patients were studied. Four categories of inducible ventricular tachycardia were studied: inducible sustained ventricular tachycardia in an antiarrhythmic drug-free state, spontaneously terminating ventricular tachycardia in an antiarrhythmic drug-free state, sustained ventricular tachycardia on antiarrhythmic therapy, and spontaneously terminating ventricular tachycardia on antiarrhythmic therapy. The ECG patterns that were statistically related to spontaneous termination of ventricular tachycardia included impingement of the QTP interval on the tachycardia cycle length (P < .001) both in the presence and absence of drugs, transient shortening of QRS just before termination, and paradoxical prolongation of QTP after abrupt shortening of ventricular tachycardia cycle length. In addition, greater beat-to-beat variances in tachycardia cycle lengths, QT intervals, and QRS durations were statistically associated with spontaneously terminating ventricular tachycardia. These ECG patterns did not occur during sustained episodes of ventricular tachycardia during the antiarrhythmic drug-free state or during ineffective antiarrhythmic drug therapy., Conclusions: A dynamic interplay between QRS duration, QT interval, and cycle length of tachycardia and their variances are associated with spontaneous termination of ventricular tachycardia in humans late after infarction. This study of ECG changes associated with spontaneous termination of ventricular tachycardia provides insight into potential mechanisms of antiarrhythmic drug efficacy.
- Published
- 1993
- Full Text
- View/download PDF
14. Infarct artery patency predicts outcome of serial electropharmacological studies in patients with malignant ventricular tachyarrhythmias.
- Author
-
Hii JT, Traboulsi M, Mitchell LB, Wyse DG, Duff HJ, and Gillis AM
- Subjects
- Aged, Arteries, Coronary Disease complications, Coronary Disease physiopathology, Electrophysiology, Female, Forecasting, Humans, Male, Middle Aged, Myocardial Infarction complications, Systole, Tachycardia, Ventricular physiopathology, Treatment Outcome, Ventricular Function, Left, Coronary Vessels physiopathology, Myocardial Infarction physiopathology, Tachycardia, Ventricular drug therapy, Vascular Patency
- Abstract
Background: Surviving myocardial cells near the infarct border zone form the arrhythmogenic substrate for sustained ventricular tachycardia (VT) in humans. Infarct-related artery (IRA) patency may modulate the electrophysiological function of this arrhythmogenic substrate and its response to antiarrhythmic drug therapy. We postulated that effective antiarrhythmic drug therapy selected during serial electrophysiological studies in patients with VT after a myocardial infarction would be identified more frequently when the IRA is patent than when chronically occluded., Methods and Results: Consecutive patients (n = 64) with documented coronary artery disease and remote myocardial infarction presenting with spontaneous sustained VT or ventricular fibrillation (VF) were studied. These patients underwent 4 +/- 2 electropharmacological studies identifying effective antiarrhythmic drug therapy in 16 (25%) patients. Drug responders did not differ significantly from nonresponders in demographic, electrocardiographic, angiographic, or hemodynamic measurements. A patent IRA was associated with antiarrhythmic drug response significantly more frequently than was an occluded IRA (45% versus 9%, p = 0.001). Patency of the IRA was the only independent predictor of response to antiarrhythmic drug therapy in this study population. The sensitivity and specificity of using a patent IRA to predict successful drug testing were 81% and 67%, respectively., Conclusions: The outcome of electropharmacological studies was predicted by the patency of the IRA. A patent IRA was associated with a greater probability of finding effective drug therapy.
- Published
- 1993
- Full Text
- View/download PDF
15. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
- Author
-
Hii JT, Wyse DG, Gillis AM, Duff HJ, Solylo MA, and Mitchell LB
- Subjects
- Aged, Anti-Arrhythmia Agents therapeutic use, Female, Heart Conduction System physiopathology, Humans, Male, Middle Aged, Quinidine adverse effects, Torsades de Pointes diagnosis, Torsades de Pointes physiopathology, Amiodarone therapeutic use, Anti-Arrhythmia Agents adverse effects, Electrocardiography, Heart Conduction System drug effects, Torsades de Pointes chemically induced
- Abstract
Background: Patients with a history of class Ia drug-induced torsade de pointes have been treated with chronic amiodarone without recurrence of torsade de pointes despite comparable prolongation of the QT interval. We hypothesized that in such patients, class Ia drugs cause nonhomogeneous prolongation of cardiac repolarization times, whereas amiodarone causes homogeneous prolongation of cardiac repolarization times., Methods and Results: Thirty-eight consecutive patients who received both class Ia drug therapy and chronic amiodarone therapy were evaluated. Standard 12-lead ECGs at baseline and during each therapy were used to calculate precordial QT interval dispersion (maximum QT in leads V1 through V6 minus minimum QT leads V1 through V6) as a measure of regional variabilities in ventricular repolarization times. Nine of these patients had torsade de pointes during class Ia drug therapy. In these nine patients, class Ia drug therapy and amiodarone significantly prolonged the maximum QT interval to comparable extents. However, class Ia drug therapy but not amiodarone therapy significantly increased precordial QT interval dispersion (101 +/- 37 versus 49 +/- 26 msec; baseline, 44 +/- 12 msec; p = 0.002). In the 29 patients without class Ia drug-induced torsade de pointes, neither class Ia drug therapy nor amiodarone therapy significantly increased QT interval dispersion (50 +/- 6 versus 69 +/- 7 msec; baseline, 54 +/- 5 msec). None of the patients with class Ia drug-induced torsade de pointes had recurrent torsade de pointes during chronic amiodarone therapy., Conclusions: An increase in regional QT interval dispersion during class Ia antiarrhythmic drug therapy is associated with torsade de pointes. Chronic amiodarone therapy in patients with a history of class Ia drug-induced torsade de pointes produces comparable maximum QT interval prolongation but does not increase QT interval dispersion. This characteristic may explain its apparent safe use in patients with a history of class Ia drug-induced torsade de pointes.
- Published
- 1992
- Full Text
- View/download PDF
16. Electrocardiographic body surface mapping in patients with ventricular tachycardia. Assessment of utility in the identification of effective pharmacological therapy.
- Author
-
Mitchell LB, Hubley-Kozey CL, Smith ER, Wyse DG, Duff HJ, Gillis AM, and Horacek BM
- Subjects
- Cardiac Pacing, Artificial, Female, Heart Conduction System physiopathology, Humans, Male, Middle Aged, Predictive Value of Tests, Tachycardia drug therapy, Tachycardia physiopathology, Anti-Arrhythmia Agents therapeutic use, Electrocardiography methods, Quinidine therapeutic use, Signal Processing, Computer-Assisted, Tachycardia diagnosis
- Abstract
Background: Body surface maps of net QRST deflection areas (isointegrals) reflect regional ventricular repolarization properties. Vulnerability to ventricular tachyarrhythmias is associated with maps that feature multiple islands (extrema) of positive and negative values; such maps reflect regional disparity of ventricular recovery properties. The value of body surface mapping in prediction of the efficacy of antiarrhythmic therapy for ventricular tachyarrhythmias has not been determined., Methods and Results: Isointegral ECG body surface mapping was performed in 51 patients with inducible ventricular tachycardia having programmed stimulation studies at baseline and after oral quinidine therapy. The degree of nondipolarity of QRST isointegral distribution was expressed by the number of extrema and by the percentage contribution of nondipolar eigenvectors after Karhunen-Loeve transformation. QRST isointegral nondipolarity was greater in ventricular tachycardia patients than in 51 age- and sex-matched normal subjects expressed as mean number of extrema (4.1 +/- 2.8 versus 2.0 +/- 0.2, respectively), mean eigenvector-determined nondipolar content percentages (12.4 +/- 10.1% versus 4.5 +/- 4.9%), prevalence of abnormal numbers of extrema (63% versus 4%), or prevalence of abnormal nondipolar content percentages (33% versus 4%) (each p less than 0.01). Quinidine prevented ventricular tachycardia induction in 14 patients. Patients for whom quinidine was or was not effective had similar nondipolarity indexes at baseline. However, maps on quinidine differed as a function of antiarrhythmic efficacy. Although effective therapy produced no significant mean changes in nondipolarity, ineffective therapy increased the number of extrema compared with baseline (5.4 +/- 3.4 versus 3.8 +/- 2.5, respectively) (p = 0.002). Individually, 43% of patients on effective therapy had drug-induced decreases in numbers of extrema compared with 14% of those on ineffective therapy (p = 0.02). Furthermore, 29% of patients on effective therapy showed drug-induced increases in numbers of extrema compared with 62% of those on ineffective therapy (p = 0.03)., Conclusions: QRST isointegral body surface mapping shows promise as a noninvasive measure of drug efficacy in patients with ventricular tachycardia.
- Published
- 1992
- Full Text
- View/download PDF
17. Melperone: electrophysiologic and antiarrhythmic activity in humans.
- Author
-
Hui WK, Mitchell LB, Kavanagh KM, Gillis AM, Wyse DG, Manyari DE, and Duff HJ
- Subjects
- Adult, Aged, Butyrophenones administration & dosage, Butyrophenones therapeutic use, Electroencephalography, Female, Half-Life, Humans, Male, Middle Aged, Tachycardia drug therapy, Tachycardia physiopathology, Anti-Arrhythmia Agents, Butyrophenones pharmacology, Electrophysiology
- Abstract
Previous studies in animals and in humans have shown that melperone, a neuroleptic butyrophenone, has class III electrophysiologic activity. However, its antiarrhythmic activity has not been assessed in humans. Accordingly, the electrophysiologic and antiarrhythmic effects of melperone were assessed in 23 patients with symptomatic ventricular tachyarrhythmias. Seventeen patients had electrophysiologic testing while receiving melperone. At oral daily dosages greater than or equal to 240 mg, melperone produced significant prolongations of QT intervals (385 +/- 11 vs. 355 +/- 22 ms, p less than 0.05), ventricular effective refractory periods (263 +/- 18 vs. 243 +/- 28 ms, p less than 0.05; 260 +/- 18 vs. 235 +/- 27 ms, p less than 0.01; and 243 +/- 23 vs. 222 +/- 28 ms, p less than 0.01; at 600-, 500-, and 400-ms pacing cycle lengths, respectively) and ventricular tachycardia (VT) cycle lengths (286 +/- 46 vs. 239 +/- 70 ms, p less than 0.05). Inducible VT was suppressed entirely in one patient. In three other patients, inducible sustained VT became nonsustained. No significant negative inotropic effects were observed. The majority of patients (70%) experienced some adverse effect, the commonest of which was neurologic. In conclusion, melperone had significant class III electrophysiologic and antiarrhythmic activity in humans. Its clinical use may be limited by the high incidence of adverse effects.
- Published
- 1990
18. Arrhythmogenic right ventricular dysplasia: a generalized cardiomyopathy?
- Author
-
Manyari DE, Klein GJ, Gulamhusein S, Boughner D, Guiraudon GM, Wyse G, Mitchell LB, and Kostuk WJ
- Subjects
- Adult, Cardiomyopathies complications, Cardiomyopathies pathology, Echocardiography, Electrocardiography, Exercise Test, Female, Heart Ventricles pathology, Heart Ventricles physiopathology, Humans, Male, Middle Aged, Stroke Volume, Technetium, Wolff-Parkinson-White Syndrome physiopathology, Cardiomyopathies physiopathology, Tachycardia etiology
- Published
- 1983
- Full Text
- View/download PDF
19. Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome.
- Author
-
Mitchell LB, Wyse DG, and Duff HJ
- Subjects
- Adult, Atrioventricular Node drug effects, Atrioventricular Node physiopathology, Dose-Response Relationship, Drug, Electrocardiography, Female, Follow-Up Studies, Humans, Male, Middle Aged, Receptors, Adrenergic, beta drug effects, Sotalol blood, Sotalol pharmacology, Wolff-Parkinson-White Syndrome physiopathology, Sotalol therapeutic use, Wolff-Parkinson-White Syndrome drug therapy
- Abstract
The beta-adrenoceptor-blocking and class III effects of sotalol were assessed in 11 patients with inducible orthodromic reciprocating tachycardia. Serum sotalol concentration, maximum exercise heart rate, and electrophysiologic study data were obtained at control, at the beta-adrenoceptor-blocking dosage (407 +/- 149 mg/day, 1.4 +/- 0.5 micrograms/ml), and at the maximum well-tolerated dosage (924 +/- 337 mg/day, 3.2 +/- 1.3 micrograms/ml). Class III effects (increases in anterograde and retrograde accessory connection effective refractory periods, ventricular effective refractory period, and the QT interval during fixed-rate atrial pacing) were evident at the beta-adrenoceptor-blocking dosage of sotalol and became more marked at the maximum well-tolerated dosage. For example, the mean anterograde accessory connection effective refractory period was significantly increased over control (272 +/- 41 msec) by the beta-adrenoceptor blocker (324 +/- 52 msec) and was further significantly increased by the maximum well-tolerated dose (364 +/- 37 msec). Similarly, the minimum preexcited RR interval during atrial fibrillation was increased in all patients at each dosage tested. Antiarrhythmic efficacy, defined by the absence of inducible, sustained, orthodromic reciprocating tachycardia and a minimum preexcited RR interval during atrial fibrillation of 300 msec or greater, was achieved in four patients at the beta-adrenoceptor-blocking dosage and in another four patients at the maximum well-tolerated dosage. These eight patients received long-term sotalol therapy and none has had recurrent, sustained reciprocating tachycardia during 15 +/- 12 months of follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1987
- Full Text
- View/download PDF
20. Amiloride. Antiarrhythmic and electrophysiologic actions in patients with inducible sustained ventricular tachycardia.
- Author
-
Duff HJ, Mitchell LB, Kavanagh KM, Manyari DE, Gillis AM, and Wyse DG
- Subjects
- Adult, Aged, Amiloride pharmacology, Electrophysiology, Female, Heart Conduction System physiopathology, Humans, Male, Middle Aged, Stroke Volume, Tachycardia diagnosis, Amiloride therapeutic use, Anti-Arrhythmia Agents, Cardiac Pacing, Artificial, Heart Conduction System drug effects, Tachycardia drug therapy
- Abstract
This study assessed the antiarrhythmic activity of amiloride in 35 patients with inducible sustained ventricular tachycardia. Patients had failed to respond to 3.6 +/- 1.0 antiarrhythmic drugs. Ventricular tachycardia was reproducibly induced by programmed electrical stimulation in all patients at the baseline study. Amiloride was given at 10 and 20 mg/day p.o. on a twice-daily schedule that achieved serum concentrations of 21 +/- 17 and 36 +/- 18 ng/ml, respectively. The mean left ventricular ejection fraction was unchanged from 36 +/- 14% at baseline to 37 +/- 17% during amiloride treatment. Amiloride significantly increased serum potassium from 4.6 +/- 0.4 to 5.1 +/- 0.4 mM. Four patients failed amiloride therapy with spontaneous nonsustained ventricular tachycardia. The remaining 31 patients were assessed by repeat programmed stimulation. Six patients had complete antiarrhythmic response, and an additional six patients had less than 15 beats of ventricular tachycardia induced. Therefore, amiloride was an efficacious antiarrhythmic treatment in 12 of 35 (34%) patients. Amiloride concentrations were significantly higher (52 +/- 20 ng/ml) in patients that responded than in patients that did not respond (30 +/- 15 ng/ml). The only electrophysiologic measurement that changed significantly was the ventricular functional refractory period (from 269 +/- 24 to 283 +/- 25 msec, p less than 0.05). Amiloride also suppressed frequent, spontaneous ventricular premature beats in eight of 15 patients (53%). No somatic side effects occurred. Two of the five patients discharged on amiloride therapy developed asymptomatic nonsustained ventricular tachycardia, and this prompted a change in antiarrhythmic therapy. Both died suddenly of arrhythmia during substitute empiric antiarrhythmic drug therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1989
- Full Text
- View/download PDF
21. Recordings of basal ventricular preexcitation from electrode catheters in patients with accessory atrioventricular connections.
- Author
-
Mitchell LB, Mason JW, Scheinman MM, Winkle RA, and Burchell HB
- Subjects
- Adolescent, Adult, Aged, Bundle-Branch Block physiopathology, Cardiac Catheterization, Child, Female, Heart Conduction System abnormalities, Heart Ventricles physiopathology, Humans, Male, Middle Aged, Pericardium physiopathology, Arrhythmias, Cardiac physiopathology, Electrocardiography, Heart Conduction System physiopathology
- Abstract
To determine the effects of ventricular preexcitation via accessory atrioventricular connections (ACs) on the sequence of basal ventricular activation, electrophysiologic study records of 22 patients with AC were reviewed. In each, AC site was confirmed by mapping done at operation. Local ventricular preexcitation (VP), defined as earlier timing of a local ventricular electrogram relative to the surface electrocardiographic QRS onset in preexcited compared with in normal QRS complexes, was assessed at the coronary sinus and at the ventricular septal summit recorded from the His bundle site. Five patients with concealed AC did not have VP. VP patterns with manifest AC were similar during average fusion QRS complexes and maximum ventricular preexcitation. Left free wall and left crux AC produced VP apparent on the ventricular electrogram recorded at the coronary sinus alone. With anteroseptal AC, VP was noted only at the ventricular septal summit. Posteroseptal AC produced VP that was apparent on the ventricular electrogram recorded at the coronary sinus and on the electrogram of the ventricular septal summit. Right free wall AC preexcited neither of these basal ventricular regions. The observation of VP patterns may help in localizing AC and may be particularly useful in patients without retrograde AC function at electrophysiologic study.
- Published
- 1984
- Full Text
- View/download PDF
22. Electropharmacology of amiodarone therapy initiation. Time courses of onset of electrophysiologic and antiarrhythmic effects.
- Author
-
Mitchell LB, Wyse DG, Gillis AM, and Duff HJ
- Subjects
- Aged, Amiodarone analogs & derivatives, Amiodarone blood, Electrophysiology, Female, Humans, Male, Middle Aged, Tachycardia, Supraventricular blood, Tachycardia, Supraventricular physiopathology, Time Factors, Ventricular Fibrillation blood, Ventricular Fibrillation physiopathology, Amiodarone therapeutic use, Tachycardia, Supraventricular drug therapy, Ventricular Fibrillation drug therapy
- Abstract
The time courses of onset of the electrophysiologic and antiarrhythmic effects of amiodarone were determined with serial electrophysiologic studies in 34 patients with inducible ventricular tachycardia. A standardized oral loading dosage was used for all patients (1,200 mg/day for 14 days; 800 mg/day for 7 days; and 400 mg/day thereafter). Eleven patients had the studies performed at baseline and after 2, 6, 10, and 20 weeks. Subsequently, 23 patients had studies at baseline and after 2 and 10 weeks. Changes in atrial, sinus, and atrioventricular nodal properties and in conduction intervals were maximal within 2 weeks (early effects). For example, atrioventricular nodal Wenckebach cycle length increased between baseline (369 +/- 80 msec) and 2 weeks (498 +/- 78 msec) (p less than 0.001) but did not change further after 10 weeks (500 +/- 89 msec). However, ventricular Class III effects required 10 weeks to become maximal (late effects). For example, the QT interval during atrial pacing increased between baseline (355 +/- 36 msec) and 2 weeks (406 +/- 37 msec) (p less than 0.001) and increased further after 10 weeks (436 +/- 45 msec) (p less than 0.001). Antiarrhythmic effects also followed different time courses of onset. Suppression of ventricular premature beats was maximal within 2 weeks. However, suppression of ventricular tachycardia inducibility and slowing of ventricular tachycardia rate was not maximal for 10 weeks. Correlations between serum desethylamiodarone concentrations and some late effects suggest that the mechanism of the time delay to maximal ventricular Class III effects may involve desethylamiodarone.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1989
- Full Text
- View/download PDF
23. Comparison of the electrophysiologic effects of intravenous and oral lorcainide in patients with recurrent ventricular tachycardia.
- Author
-
Echt DS, Mitchell LB, Kates RE, and Winkle RA
- Subjects
- Administration, Oral, Aged, Anti-Arrhythmia Agents blood, Electrocardiography, Heart Ventricles, Humans, Infusions, Parenteral, Injections, Intravenous, Middle Aged, Piperidines blood, Recurrence, Anti-Arrhythmia Agents administration & dosage, Benzeneacetamides, Piperidines administration & dosage, Tachycardia drug therapy
- Abstract
The electrophysiologic effects of intravenous lorcainide (2.2 mg/kg) in 10 patients were compared with the electrophysiologic effects of oral lorcainide (mean dose 400 mg/day for 8 days) in 11 patients, all with recurrent ventricular tachycardia that could be induced with programmed stimulation. Intravenous and oral lorcainide resulted in similar prolongation of the QRS, QT, and HV intervals, but only oral lorcainide resulted in prolongation of the AH interval and atrial and ventricular effective refractory periods. After both oral and intravenous lorcainide, ventricular tachycardia could still be induced, but the arrhythmia was slower and better tolerated hemodynamically. The mean plasma lorcainide level during a maintenance intravenous infusion was 1254 +/- 662 ng/ml compared with a lorcainide level of 562 +/- 41 ng/ml and a norlorcainide level of 1212 +/- 653 ng/ml after oral dosing. No norlorcainide was detected in plasma after intravenous lorcainide. These data suggest that the short-term electrophysiologic effects of intravenous lorcainide may be different from those of short-term therapy with the oral drug. These differences should be considered during short-term studies of lorcainide.
- Published
- 1983
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.